Pinheiro Neto Advogados advised Emerging Variant on the delisting tender offer for the acquisition of common shares related to the conversion of Zamp’s registration as a publicly held company. The transaction involved Emerging Variant’
Tags :Pinheiro Neto
Pinheiro Neto acted as deal counsel on the 2nd issuance of commercial notes, secured, in a sigle series, by Total Biotecnologia Indústria e Comércio, as per CVM Resolution 160, in the total amount of
TTR Data‘s monthly report revealed that 671 transactions moved a total of BRL 120.0bn by May 2025, which represents a 1% decrease in the number of transactions compared to the same period in 2024.However, the capital raised
Pinheiro Neto Advogados acted as counsel to the issuer, and Lefosse acted as counsel to the underwriters on the 13th issuance of simple debentures, not convertible into shares, in a single series, unsecured, for public
Madrona Advogados advised Companhia de Saneamento Básico do Estado de São Paulo (Sabesp) on the acquisition of 70% of the share capital of each of the companies Águas de Andradina and Águas de Castilho
i2a Advogados and Pinheiro Neto advised management company Patria Investimentos on the acquisition of six FIIs from Genial Investimentos, which adds around BRL 2.5 billion to the company’s assets under management. Of the total
Pinheiro Neto Advogados advised Vórtx on the acquisition of all issued quotas of Grafeno, representing 100% of its total share capital. Trench Rossi Watanabe advised Grafeno. As part of the transaction, some current shareholders of
Machado Meyer advised GIC (through its fund NY FIP) on the indirect acquisition of 45% of the share capital of Entrevias Concessionária de Rodovias. The sellers are funds managed by Patria Investimentos, which was advised
Pinheiro Neto Advogados acted as deal counsel on the 6th issuance of simple debentures, non convertible into shares, in two single series, for public distribution, by Jalles Machado, in accordance with CVM 160. Banco Santander (Brasil)
Pinheiro Neto advised on the transaction in which Sanofi completed the sale to CD&R of a 50% controlling stake in Opella, retaining a 48.2% stake and Bpifrance holding 1.8%. The transaction had a net cash value
